You are using an outdated browser. We suggest you update your browser for a better experience.
Click here
for update.
Close this notification.
Skip to main content
Skip to search
CCO
Cancer Care Ontario
Ontario Renal Network
EN
FR
Recently Viewed
Cancer Care Ontario
Open Navigation
Close Navigation
Home
Types of Cancer
Cancer Treatments
Get Checked for Cancer
Find Services
Indigenous
Ontario Cancer Plan
COVID-19
Drug Formulary
Drugs
Regimens
Funding & Reimbursement
Side Effects
Drug Safety & Information
Pre-Printed Orders
What’s New
Guidelines & Advice
Browse Guidelines
Types of Cancer
Modality of Care
Cancer Continuum
Most Popular Documents
What’s New in Guidelines & Advice
About Guidelines
Toolkits
Education & Events
Managing Symptoms
COVID-19 Resources
Pathway Maps
Browse Pathway Maps
Bladder Cancer
Breast Cancer
Cervical Cancer
Colorectal Cancer
Endometrial Cancer
Esophageal Cancer
Lung Cancer
Oropharyngeal Cancer
Ovarian Cancer
Prostate Cancer
Skin Cancer
Soft Tissue Sarcoma
Thyroid Cancer
Cervical Lymphadenopathy in Adults Pathway Map
Hepatocellular Cancer Pathway Map
Data & Research
Accessing Data
View Data
Submitting Data
Our Research
Funding Opportunities
Open Search
Close Search
Open Navigation
Close Navigation
All
Drug Formulary
Guidelines and Advice
Data
Cancer Care Ontario
General Cancer Info
Pathway Maps
Sort by
Most Relevant
Letter (A-Z)
Most Recent
You are here
Search
You may filter this list by entering a keyword to the right
Refine Your Results
4 Results
Regimen
BINIENCO
Cancer Type:
Lung,
Non-Small Cell
Show More
Show more tags
, Show Less
Show fewer tags
Intent:
Palliative
Drugs Used:
binimetinib
(Unfunded)
,
encorafenib
(Unfunded)
...
Show more tags
, Collapse
Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Regimen
BORTDEXAPOMA
Cancer Type:
Hematologic,
Multiple Myeloma
Show More
Show more tags
, Show Less
Show fewer tags
Intent:
Palliative
Funding:
New Drug Funding Program
Bortezomib - In Combination with Pomalidomide and Dexamethasone for Previously Treated Multiple Myeloma
ODB - General Benefit
dexamethasone
Exceptional Access Program
pomalidomide - For patients with relapsed and/or refractory multiple myeloma, according to specific criteria
Show More
Show more tags
, Show Less
Show fewer tags
Drugs Used:
bortezomib
,
dexamethasone
,
pomalidomide
...
Show more tags
, Collapse
Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Regimen
BORTDEXALENA+DARA; LENA+DARA(MNT)
Cancer Type:
Hematologic,
Multiple Myeloma
Show More
Show more tags
, Show Less
Show fewer tags
Intent:
Palliative
Funding:
New Drug Funding Program
Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
ODB - General Benefit
dexamethasone
Show More
Show more tags
, Show Less
Show fewer tags
Drugs Used:
daratumumab
(Unfunded)
,
bortezomib
(Unfunded)
,
lenalidomide
(Unfunded)
,
dexamethasone
...
Show more tags
, Collapse
Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Apr 2025
Regimen
BELZ
Cancer Type:
Endocrine,
Pancreatic Neuroendocrine,
Genitourinary,
Renal cell / Kidney
Show More
Show more tags
, Show Less
Show fewer tags
Intent:
Curative, Palliative
Funding:
Exceptional Access Program
Belzutifan – For the treatment of adult patients with von Hippel-Lindau (vHL) disease, based on criteria
Show More
Show more tags
, Show Less
Show fewer tags
Drugs Used:
belzutifan
...
Show more tags
, Collapse
Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Apr 2025